Integrated Diagnostics Obtains $47M in Funding to Support Commercialization of Xpresys Lung Test | GenomeWeb

NEW YORK (GenomeWeb) – Integrated Diagnostics said this week that it has obtained $47.25 million in funding, $30.25 million from the closing of its Series B round and $17 million in non-dilutive debt financing from Life Sciences Alternative Funding.

The proceeds will be used primarily for commercialization of Indi's proteomic lung cancer test, Xpresys Lung, supporting an expansion of the company's sales staff and clinical infrastructure as well as efforts to obtain reimbursement for the test, Indi CEO Albert Luderer told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.